Haeseong Park, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses findings from a Phase I trial (NCT05372614) of trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, with neratinib, a tyrosine kinase inhibitor (TKI), in patients with solid tumors with HER2 alterations. Previous studies have shown that addition of a TKI to trastuzumab deruxtecan increases the efficacy of the latter. The current trial will primarily assess the safety of the treatment combinations, and future studies might assess the strategy in HER2-low tumors. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
